Rein Therapeutics, Inc (RNTX)

In November 2025, the company announced positive topline data from Cohort 2 of the Phase 1b clinical trial of LTI-03 in IPF patients, received FDA clearance to resume its U.S. Phase 2 trial of LTI-03 in Idiopathic Pulmonary Fibrosis, was upgraded to "Buy" from "Hold" by Brookline, had its price target decreased by 20.00% to $8.16, and reported its Q3 2025 earnings, with an EPS of -$0.21, surpassing the consensus estimate of -$0.24. In January 2026, Rein Therapeutics received Orphan Drug Designation from the European Medicines Agency (EMA) for LTI-03 and had its price target increased by 25.00% to $10.20. On January 29, 2026, the 10-day moving average for RNTX crossed bullishly above the 50-day moving average. In February 2026, Brookline downgraded Rein Therapeutics to "Hold" from "Buy," citing near-term financing risk.

Direct demand seasonality is not a primary factor for Rein Therapeutics, as its therapies are still in development. The company's "Seasonality Score" is -19, likely pertaining to historical stock performance seasonality. The demand for its future products will primarily be driven by clinical trial success, regulatory approvals, and the prevalence of the diseases they aim to treat.

Rein Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics for unmet medical needs, particularly in orphan pulmonary and fibrosis indications. The company's lead product candidate is LTI-03, in Phase 2 clinical trials for IPF. LTI-01 has completed Phase 1b and Phase 2a clinical trials for LPE. Earlier descriptions also mentioned ALRN-6924, a cell-permeating peptide for reactivating tumor suppression in wild-type p53 cancers, though the recent focus has shifted to fibrosis. Another product candidate, LTI-05, is in development for cystic fibrosis.

Rein Therapeutics is headquartered in Austin, Texas, United States. Clinical trials for LTI-03 have a global reach, with approximately 20 U.S. clinical sites across states such as Alabama, California, Florida, Massachusetts, and Texas. There are about 30 international sites in the United Kingdom, Germany, Poland, and Australia.

Rein Therapeutics rebranded from Aileron Therapeutics, Inc. in October 2023, focusing on combating fibrosis. The company's news sentiment score is 0.55, lower than the average of 0.79, suggesting a neutral to slightly positive public perception. RNTX has underperformed the broader U.S. market over the past year. Analyst consensus currently rates the stock as a "Hold." Zacks Investment Research rates Rein Therapeutics Inc. as a "Zacks Rank 3" (Hold), with a "Value Score" of F, but a "Growth Score" and "Momentum Score" of B.

Rein Therapeutics has significant institutional ownership, with 46 institutional owners holding 90.89% of the stock. Major institutional owners include Voss Capital, LLC, BIOS Capital Management, LP, Vanguard Group Inc, Prosight Management, LP, and University Of Texas/texas Am Investment Managment Co. Individual (insider) ownership stands at 81.04%, with key individual owners being Muneer A. Satter (63.19%), Reinhard J. Ambros (9.70%), and Brian M. Gallagher Jr. (5.45%).